June 22, 2020 – Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., announces completion of merger with Progenics Pharmaceuticals, Inc. Learn More
Improved diagnostic information for better patient management
Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
Providing you with important information regarding our response to the C0VID-19 pandemic.
(updated 5/29/2020)
View a recent Lantheus webinar:
COVID-19: Clinical Experiences from the Front Line in NYC
Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.